Head-to-head evidence
Desidustat vs Molidustat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline
Desidustat · Oxemia
Marketed by Zydus Lifesciences
NCT04012957 · Phase 3 · completed
The study was randomized and used an active darbepoetin comparator, but it was open-label and its primary outcome was change in hemoglobin, a surrogate laboratory measure rather than a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Molidustat
Developed by Bayer
NCT03543657 · Phase 3 · completed
The trial randomized 229 participants to molidustat or darbepoetin alfa with matching placebos and quadruple blinding. Its primary endpoints were hemoglobin measures, which are laboratory surrogate outcomes, and no primary results or statistical comparison are available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Desidustat's landscape · Molidustat's landscape